Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDWD MediWound	$18.10 -2.5%	$19.62	$14.14 ▼ $22.50	$195.62M	0.21	68,494 shs	117,753 shs
NUVB Nuvation Bio	$2.75 -0.4%	$2.21	$1.54 ▼ $3.45	$935.72M	1.35	4.65 million shs	4.46 million shs
OCS Oculis	$17.90 +0.6%	$18.56	$10.79 ▼ $23.08	$781.55M	0.27	12,414 shs	2,003 shs
ORIC Oric Pharmaceuticals	$9.66 -2.7%	$10.30	$3.90 ▼ $14.67	$938.21M	1.69	1.30 million shs	650,938 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDWD MediWound	0.00%	-2.84%	-9.73%	-11.62%	+3.61%
NUVB Nuvation Bio	0.00%	+19.57%	+22.39%	+21.95%	+0.55%
OCS Oculis	0.00%	-1.70%	-1.49%	+0.28%	+49.17%
ORIC Oric Pharmaceuticals	0.00%	+4.55%	-13.29%	+104.23%	-2.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MDWD MediWound	1.5421 of 5 stars	3.5	1.0	0.0	1.0	0.8	0.6
NUVB Nuvation Bio	2.335 of 5 stars	3.6	1.0	0.0	2.3	3.3	0.0
OCS Oculis	3.0703 of 5 stars	3.5	5.0	0.0	3.3	0.0	0.6
ORIC Oric Pharmaceuticals	4.7228 of 5 stars	4.5	3.0	4.4	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDWD MediWound	3.00	Buy	$32.25	78.18% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	166.67% Upside
OCS Oculis	3.00	Buy	$35.33	97.39% Upside
ORIC Oric Pharmaceuticals	2.90	Moderate Buy	$17.63	82.45% Upside

Current Analyst Ratings Breakdown

Latest MDWD, OCS, ORIC, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
8/14/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
8/13/2025	ORIC Oric Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/12/2025	ORIC Oric Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDWD MediWound	$20.22M	9.68	N/A	N/A	$2.89 per share	6.26
NUVB Nuvation Bio	$14.36M	65.18	N/A	N/A	$1.10 per share	2.50
OCS Oculis	$780K	1,001.94	N/A	N/A	$1.91 per share	9.37
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-142.18%	-87.63%	-38.99%	N/A
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	11/5/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/26/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.89	N/A	N/A	N/A	N/A	-51.75%	-47.09%	N/A

Latest MDWD, OCS, ORIC, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/26/2025	Q2 2025	OCS Oculis	-$0.53	N/A	N/A	N/A	$0.14 million	N/A
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	-$1.23	-$0.68	-$1.23	$5.68 million	$5.71 million
8/12/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	-$0.47	-$0.01	-$0.47	N/A	N/A
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDWD MediWound	N/A	2.15	1.99
NUVB Nuvation Bio	0.13	9.39	9.38
OCS Oculis	N/A	4.79	4.79
ORIC Oric Pharmaceuticals	N/A	16.13	12.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDWD MediWound	46.83%
NUVB Nuvation Bio	61.67%
OCS Oculis	22.30%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
MDWD MediWound	9.20%
NUVB Nuvation Bio	29.93%
OCS Oculis	N/A
ORIC Oric Pharmaceuticals	6.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
ORIC Oric Pharmaceuticals	80	97.12 million	90.50 million	Optionable

MDWD, OCS, ORIC, and NUVB Headlines

Recent News About These Companies

Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals

August 17 at 8:58 AM | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research

August 17 at 8:29 AM | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at JPMorgan Chase & Co.

August 17 at 3:31 AM | americanbankingnews.com

HC Wainwright Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00

August 17 at 2:05 AM | americanbankingnews.com

Q3 EPS Estimate for Oric Pharmaceuticals Reduced by Analyst

August 17 at 2:23 AM | americanbankingnews.com

JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price

August 16 at 11:48 AM | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright

August 16 at 8:07 AM | marketbeat.com

Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim

August 15 at 10:14 AM | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Earns "Buy" Rating from Guggenheim

August 15 at 3:09 AM | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 14 at 5:42 PM | marketbeat.com

Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize

August 14 at 3:32 PM | pharmexec.comP

Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs

August 13, 2025 | fiercebiotech.comF

Oric Pharmaceuticals Focuses on Lead Clinical Programs

August 12, 2025 | msn.com

Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c)

August 12, 2025 | msn.com

Oric Pharmaceuticals Logs Wider 2Q Loss, Plans to Cut 20% of Workforce

August 12, 2025 | marketwatch.com

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

August 12, 2025 | globenewswire.com

Vivo Capital LLC Purchases 802,632 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

August 9, 2025 | marketbeat.com

Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday

August 9, 2025 | americanbankingnews.com

ORIC Pharmaceuticals: What It Takes To Be Best In Class

August 7, 2025 | seekingalpha.com

Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDWD, OCS, ORIC, and NUVB Company Descriptions

MediWound NASDAQ:MDWD

$18.10 -0.47 (-2.53%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$18.10 0.00 (0.00%)

As of 08/15/2025 04:10 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Nuvation Bio NYSE:NUVB

$2.75 -0.01 (-0.36%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$2.73 -0.02 (-0.73%)

As of 08/15/2025 07:59 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Oculis NASDAQ:OCS

$17.90 +0.10 (+0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$17.95 +0.05 (+0.28%)

As of 08/15/2025 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Oric Pharmaceuticals NASDAQ:ORIC

$9.66 -0.27 (-2.72%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$9.78 +0.13 (+1.29%)

As of 08/15/2025 07:13 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time